Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. ... [NEWS]
CALGARY, May 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
(“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that it has begun
patient enrolment in a clinical trial using intravenous administration of
REOLYSIN® in combination with cyclophosphamide, a chemotherapeutic agent
as well as immune modulator, in patients with advanced cancers. The
Principal Investigators are Dr. James Spicer of King’s College in London,
Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS
Foundatio…
New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in ... [NEWS]
- Fifth International Phase III Study Shows Positive Results with X-ray
Data -
NUTLEY, N.J., May 9 /PRNewswire/ — Roche today announced one-year
results from a new two-year Phase III study showing that ACTEMRA™
(tocilizumab) can significantly inhibit progression of structural damage to
joints in patients with rheumatoid arthritis (RA), a critical measure of
effectiveness of an RA treatment. The study also demonstrated that ACTEMRA
reduces disease signs and…
Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial [NEWS]
MIAMI, May 8 /PRNewswire/ — Globus Medical, Inc., the largest
privately held spinal implant manufacturer in the world and a recognized
leader in motion preservation technology, today announced the completion of
enrollment in its SECURE®-C Cervical Artificial Disc IDE study. The
SECURE®-C device is designed to mimic the normal motion of the spine in
order to alleviate pain and restore function as an alternative to fusion in
the treatment of symptomatic cervical disc disease. A total of 380 patient…
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the ... [NEWS]
VYVANSE demonstrated significant improvement in ADHD symptoms in adults
WASHINGTON, May 8 /PRNewswire-FirstCall/ — Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, today
presented the results of a phase III pivotal study in which VYVANSE
demonstrated significant improvements in Attention Deficit Hyperactivity
Disorder (ADHD) symptoms in adults and met all safety and efficacy
endpoints.
“Adults with ADHD often find it challenging to focus and organize
…
Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the ... [NEWS]
VYVANSE demonstrated significant improvement in ADHD symptoms in adults
WASHINGTON, May 8 /PRNewswire-FirstCall/ — Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, today
presented the results of a phase III pivotal study in which VYVANSE
demonstrated significant improvements in Attention Deficit Hyperactivity
Disorder (ADHD) symptoms in adults and met all safety and efficacy
endpoints.
“Adults with ADHD often find it challenging to focus and organize
…
Steno Bacterium Sequenced Scientists from the Wellcome Trust Sanger Institute have genetically sequenced the Steno bacterium.
Steno is a quickly emerging hospital superbug that is extremely drug resistant.
There are no known drugs capable of...
Hormone Increases Desire For Food Photo courtesy PDPhoto.org
Researchers have discovered that the hormone ghrelin plays an important role in overeating by stimulating the brain's pleasure center.
Ghrelin stimulates our appetite and also increases...
Cancer Gene Researchers have discovered a previously unknown cancer causing gene.
This gene, RBM3, also contains a protein with the same name. They are both important to the process of normal cell division.
In...
Fast Food and Liver Damage Studies have shown that eating too much fast food can lead to liver damage.
A diet high in fat and sugar can cause serious diseases of the liver such as cirrhosis.
However,...
